Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

NCT06517511 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Selinexor Oral Tablet [Xpovio]
DRUG: R-CHOP Protocol

Sponsor

Sun Yat-sen University

Collaborators

[object Object]